Hepatitis C screening during SARS-CoV-2 testing or vaccination. Experience in an area of southern Italy in the province of Salerno

To the editor,

INTRODUCTION

Nowadays hepatitis C can be cured in nearly all affected people by extremely effective and safe therapies, therefore the current challenges are case finding and access to treatment. The latest estimates by the WHO report 58 million hepatitis C cases around the world and about 1.5 million new infections per year. Some experts believe that the Global Health Sector Strategy goal of eliminating viral hepatitis ‘as a major public health threat’ by 2030 is somewhat optimistic in relation to the current global situation. The SARS-CoV-2 pandemic has hampered the hepatitis C testing and treatment, and it is estimated that it could be a major obstacle to hepatitis C elimination. Among the efforts to counter this scenario, it was proposed to exploit the current pandemic to enhance hepatitis C screening. The first experiences of combined HCV/SARS-CoV-2 testing have already been carried out, while although it was proposed, there are still no data on the combination of screening for hepatitis C and SARS-CoV-2 vaccination. For these reasons, we started a screening program for hepatitis C simultaneously with the SARS-CoV-2 testing or vaccination. This project took place in an urban area in the province of Salerno (Campania region).

METHODS

Screening for SARS-CoV-2 infection was performed at the USCA (Unità Speciali di Continuità Assistenziale) of Baronissi using nasopharyngeal swab, NPS (Greiner bio-one), to search for the viral RNA, while the SARS-CoV-2 vaccination (using Pfizer-BioNTech, Moderna, or Oxford-AstraZeneca vaccine) took place at the Fisciano vaccination centre. The screening for hepatitis C, which was proposed to all people over the age of 17 after obtaining written informed consent, was carried out at both sites using the Anti-HCV TEST WB/S/P (Türklab) for the identification of anti-HCV antibodies. In the time period 1 May–20 July 2021, 3735 people underwent SARS-CoV-2 testing, 5095 were vaccinated against SARS-CoV-2, and 3000 were screened for HCV. Statistical analyses were conducted using GraphPad Prism 9.2.0. The study was approved by our local Ethics Committee (Comitato etico Campania Sud).

RESULTS

Among the 3735 people who carried out the NPS, 1951 (1232 different people) met the criteria for hepatitis C screening. Of these, 373/1232 (30.3%; 95% CI, 27.8%–32.9%) agreed to carry out the HCV-Ab test; 221/3735 (5.9%; 95% CI, 5.2%–6.7%) NPSs tested positive, while all HCV-Ab tests resulted negative. Among the 5095 people who underwent COVID-19 vaccination, 1952 (38.3%; 95% CI, 37.0%–39.7%) performed the screening for hepatitis C, and five of these (0.3%; 95% CI 0.1%–0.6%) were HCV-Ab positive. Furthermore, 675 HCV-Ab tests were performed for people who accompanied relatives to have a NPS; among the latter, two subjects (0.3%) resulted positive. The total prevalence of HCV-Ab positivity among people who agreed to take part in this project was therefore 0.2%. Regarding the seven anti-HCV-Ab positive people: the average age was 52.7 years; positive cases were found in the age classes 31–40 (3), 41–50 (1), 51–60 (1), 71–80 (1), >80 (1); four were women and three were men; 2/7 were of foreign nationality; 5/7 reported awareness of their status. Among these latter subjects, four had previous treatment with DAAs with a SVR rate of 100%, while one of them did not undergo any therapy. The other two people who tested positive for HCV-Ab were not aware of their positivity and they did not undergo any therapy. These last three subjects were referred to our Unit, and after checking the HCV RNA status and genotype [3a (2), 1a (1)] they began antiviral therapy with DAAs. The prevalence of active HCV infection found in this project was therefore 0.1%. The total cost of performing these adjunctive HCV testing was of 11100 euros overall or 3.7 euros per screened patient. Table 1 summarizes the results of this project.

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

© 2022 University of Salerno. Liver International published by John Wiley & Sons Ltd.
DISCUSSION AND CONCLUSIONS

This project confirms that screening for hepatitis C is possible during testing for SARS-CoV-2, and demonstrates that COVID-19 vaccination could be an opportunity for HCV-Ab testing. However, we registered a high refusal rate for hepatitis C screening during both testing or vaccination for SARS-CoV-2. By administering the informed consent, all the subjects were briefly informed about HCV infection and its therapeutic options and also asked to provide the explanation for refusal. The refusal rate was significantly lower (p < .0001, chi-square test) in people who received a COVID-19 vaccine than in those who were tested for SARS-CoV-2 RNA. The reasons for HCV-Ab test refusal were lack of knowledge of the disease (55%), fear of positive results (40%), and distrust of the health system (5%). Another aspect to consider is that the prevalence of HCV-Ab positivity was found to be lower compared to that reported in the Italian general population (~2%, with a higher prevalence in southern regions compared to northern ones based on historical data). This could be partly explained by data reporting that in Italy the prevalence of HCV infection increases with age (a peak of 7% of HCV-Ab positive people was documented in the 1935–1944 age group), and as the elders represented a minority of the people involved in our project, probably because they had already been vaccinated for SARS-CoV-2 at the time this project took place. On the other hand, we cannot exclude that those results may be also partially influenced by a ‘selection bias’, being those with mistrust in the health system ‘self-selecting’ themselves out of the screening by not performing it. These aspects lead us to question the cost/benefit ratio of hepatitis C screening during current SARS-CoV-2 testing or vaccination programs.

KEYWORDS
combined screening, COVID-19 vaccination, hepatitis C, SARS-CoV-2

ACKNOWLEDGMENT
Open Access Funding provided by Universita degli Studi di Salerno within the CRUI-CARE Agreement.

CONFLICT OF INTEREST
None.

FUNDING INFORMATION
There is no financial support to be declared for this study.

TABLE 1 Characteristics of people screened for hepatitis C during SARS-CoV-2 testing or vaccination

| Overall HCV testing (3000) | HCV/SARS-CoV-2 testing = 373 (12.4% of the total) | HCV testing/SARS-CoV-2 vaccination = 1952 (65.1% of the total) | HCV testing only = 675 (22.5% of the total) |
|---------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|
| Average age | 43.4 years | 46.2 years | 41.6 years | 47 years |
| Age classes | | | | |
| ≤20 | 80 (2.7%) | 20 (5.4%) | 47 (2.4%) | 13 (1.9%) |
| 21–30 | 529 (17.6%) | 38 (10.2%) | 440 (22.5%) | 51 (7.6%) |
| 31–40 | 735 (24.5%) | 64 (17.2%) | 502 (25.7%) | 169 (25.0%) |
| 41–50 | 742 (24.7%) | 117 (31.4%) | 418 (21.4%) | 207 (30.7%) |
| 51–60 | 453 (15.1%) | 64 (17.2%) | 277 (14.2%) | 112 (16.6%) |
| 61–70 | 324 (10.8%) | 46 (12.3%) | 204 (10.5%) | 74 (11.0%) |
| 71–80 | 114 (3.8%) | 21 (5.6%) | 51 (2.6%) | 42 (6.2%) |
| >80 | 23 (0.8%) | 3 (0.8%) | 13 (0.7%) | 7 (1.0%) |
| Sex (M/F) | 1369/1631 | 177/196 | 877/1075 | 315/360 |
| Not Italian | 46 (1.5%) | 7 (1.9%) | 29 (1.5%) | 10 (1.5%) |
| HCV-Ab test positive | 7 (0.2%) | 0 | 5 | 2 |
| Awareness of HCV-Ab status | 5/7 (71.4%) | – | 5 | 0 |
| Previous treatment | 4/7 (57.1%) | – | 4 | 0 |
| HCV-RNA positive | 3/7 (42.9%) | – | 1 | 2 |

1Internal Medicine and Hepatology Unit, Department of Medicine, Surgery and Dentistry, “Scuola Medica Salernitana”.
University of Salerno, Salerno, Italy
2Department of Internal Medicine - Unit of Hepatology and Interventional Ultrasonography, OORR Area Stabiese, Plesso Nuovo Gragnano, Naples, Italy

Correspondence
Marcello Persico, Internal Medicine and Hepatology Unit, Department of Medicine, Surgery and Dentistry, “Scuola Medica Salernitana”, University of Salerno, Via Salvador Allende, Salerno 84081, Italy.
Email: mpersico@unisa.it

ORCID
Pietro Torre 🌐 https://orcid.org/0000-0001-8245-5305
Marcello Persico 🌐 https://orcid.org/0000-0002-1399-6498

REFERENCES
1. https://www.who.int/news-room/fact-sheets/detail/hepatitis-c
2. Cox AL, El-Sayed MH, & Kao JH, et al. Progress towards elimination goals for viral hepatitis. Nat rev gastroenterol Hepatol. 2020;17(9):533-542. https://doi.org/10.1038/s41575-020-0332-6
3. Aghemo A, Masarone M, Montagnese S, et al. Assessing the impact of COVID-19 on the management of patients with liver diseases: a national survey by the Italian association for the study of the liver. Dig Liver Dis. 2020 Sep;52(9):937-941. doi:10.1016/j.dld.2020.07.008 Epub 2020 Jul 10. PMID: 32703730; PMCID: PMC7351426.
4. Blach S, Kondili L, Aghemo A, et al. Impact of COVID-19 on global HCV elimination efforts. J Hepatol. 2021 Jan;74(1):31-36. doi:10.1016/j.jhep.2020.07.042 Epub 2020 Aug 7. PMID: 32777322; PMCID: PMC7411379.
5. Crespo J, Díaz-González Á, Iruzubieta P, Llerena S, Cabezas J. SARS-CoV-2 massive testing: a window of opportunity to catch up with HCV elimination. J Hepatol. 2021 Apr;74(4):966-967. doi:10.1016/j.jhep.2020.10.001 Epub 2020 Oct 9. PMID: 33039405; PMCID: PMC7544696.
6. Coppola C, Masarone M, Bartoli M, et al. Associated screening for HCV and SARS-CoV2 infection in an urban area of Southern Italy: a cohort study. Journal of Viral Hepatitis. 2022;29(2):171-173. https://doi.org/10.1111/jvh.13623
7. Giacomelli A, Pagani G, Conti F, Bassoli C, Galli M. Detecting HCV infection by means of mass population SARS-CoV-2 screening: a pilot experience in northern Italy. J Hepatol. 2021 Aug;75(2):484-486. doi:10.1016/j.jhep.2020.12.026 Epub 2021 Jan 13. PMID: 33453329; PMCID: PMC7804391.
8. Crespo J, Díaz-González Á, Cabezas J. HCV detection is possible during SARS CoV-2 testing; and throughout COVID-19 vaccination? J Hepatol. 2021 Aug;75(2):486-487. doi:10.1016/j.jhep.2021.04.043 Epub May 7, 2021. PMID: 33971225; PMCID: PMC8103740.
9. Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol. 2014 Nov;61(1 Suppl):S45-S57. doi:10.1016/j.jhep.2014.07.027 Epub 2014 Jul 30. PMID: 25086286.
10. Andriulli A, Stroffolini T, Mariano A, et al. Declining prevalence and increasing awareness of HCV infection in Italy: a population-based survey in five metropolitan areas. Eur J Intern Med. 2018 Jul;53:79-84. doi:10.1016/j.ejim.2018.02.015 Epub 2018 Feb 21. PMID: 29475770.